Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 2.
doi: 10.1111/epi.18440. Online ahead of print.

Appropriate selection of participants in pediatric developmental and epileptic encephalopathy trials: Lessons learned and future opportunities

Dennis Dlugos  1   2   3 , Meryl Lozano  3 , Bree DiVentura  3 , Gail Farfel  4 , Renée A Shellhaas  3   5 , Joseph E Sullivan  3   6 , Liu Lin Thio  3   5 , Sudha Kilaru Kessler  1   2   3 , Lynette G Sadleir  3   7 , Jacqueline French  3   8
Affiliations

Appropriate selection of participants in pediatric developmental and epileptic encephalopathy trials: Lessons learned and future opportunities

Dennis Dlugos et al. Epilepsia. .

Abstract

We evaluate the impact of independent, central review of epilepsy syndromes and seizure classification in randomized controlled treatment trials of Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). Central review of two recent trials determined that 5.6% of enrolled DS participants and 3.4% of enrolled LGS participants pending randomization did not meet criteria for the epilepsy syndrome under study. Furthermore, 23% of DS participants and 32% of LGS participants had at least one seizure reclassified; 63.8% of DS sites and 78% of LGS sites had at least one participant with a seizure reclassification. Independent, central review of participants in pediatric ASM trials improves consistency across study sites, as well as overall accuracy of syndromic diagnosis and seizure classification, and may reduce placebo response rate.

Keywords: Dravet syndrome; Lennox–Gastaut syndrome; developmental and epileptic encephalopathies; fenfluramine; randomized control trials.

PubMed Disclaimer

References

REFERENCES

    1. French JA, Friedman D. Appropriate selection of participants for clinical trials in epilepsy. Lancet Neurology. 2023;22(7):554–555. https://doi.org/10.1016/S1474‐4422(23)00202‐8
    1. French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive Everolimus therapy for treatment‐resistant focal‐onset seizures associated with tuberous sclerosis: a phase 3, randomized, placebo‐controlled trial. Lancet. 2016;388:2153–2163.
    1. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug‐resistant seizures in the Dravet syndrome. NEJM. 2017;376:2011–2020.
    1. Thiele EA, Marsh ED, French JA, Mazurkiewicz‐Beldzinska M, Benbadis S, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox‐Gastuat syndrome: a randomized, double‐blind, placebo‐controlled phase 3 trial. Lancet. 2018;391:1085–1096.
    1. Lagae L, Sullivan J, Knupp K, Laux L, Pollster T, Nikanorova M, et al. Fenfluramine hydrochloride for treatment of seizures in Dravet syndrome: a randomized, double‐blind, placebo‐controlled trial. Lancet. 2019;394:2243–2254.

LinkOut - more resources